Ember Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMBT research report →
Companywww.embertx.com
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes.
- CEO
- Joseph Hernandez
- IPO
- 2015
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $398
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -11.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 10.25%
- ROIC
- 46.02%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,242 · -42.30%
- EPS
- $-0.01 · -43.18%
- Op Income
- $-17,421
- FCF YoY
- 25.98%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.44
- Avg Volume
- 1.73K
Get TickerSpark's AI analysis on EMBT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 11, 16 | Rudolf John C | buy | 5,986 |
| Feb 11, 16 | Rudolf John C | buy | 455 |
| Feb 10, 16 | Rudolf John C | buy | 500 |
| Feb 10, 16 | Rudolf John C | buy | 565 |
| Feb 5, 16 | Rudolf John C | buy | 231 |
| Feb 5, 16 | Rudolf John C | buy | 560 |
| Feb 4, 16 | Rudolf John C | buy | 355 |
| Feb 2, 16 | Rudolf John C | buy | 14 |
| Feb 1, 16 | Rudolf John C | buy | 999 |
| Feb 1, 16 | Rudolf John C | buy | 1,200 |
Our EMBT Coverage
We haven't published any research on EMBT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EMBT Report →